Entera Bio Ltd.

NasdaqCM:ENTX Stock Report

Market Cap: US$81.7m

Entera Bio Management

Management criteria checks 2/4

Entera Bio's CEO is Miranda Toledano, appointed in Jul 2022, has a tenure of 7.83 years. total yearly compensation is $1.48M, comprised of 33.1% salary and 66.9% bonuses, including company stock and options. directly owns 0.87% of the company’s shares, worth $708.12K. The average tenure of the management team and the board of directors is 2.2 years and 3.2 years respectively.

Key information

Miranda Toledano

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage33.06%
CEO tenure4yrs
CEO ownership0.9%
Management average tenure2.2yrs
Board average tenure3.2yrs

Recent management updates

Recent updates

Analysis Article • Jan 31

Is Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jul 17

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Dec 07

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Entera Bio...
Analysis Article • Jul 12

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Entera...
Analysis Article • Mar 23

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 31

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Feb 15

Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 13

Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 11

Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M

Entera Bio press release (NASDAQ:ENTX): 1H GAAP EPS of -$0.24. Revenue of $0.11M (-59.3% Y/Y). Shares +3.68% PM
Analysis Article • Jun 10

We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jan 21

Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO Compensation Analysis

How has Miranda Toledano's remuneration changed compared to Entera Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$12m

Dec 31 2025US$1mUS$490k

-US$11m

Sep 30 2025n/an/a

-US$11m

Jun 30 2025n/an/a

-US$11m

Mar 31 2025n/an/a

-US$10m

Dec 31 2024US$1mUS$419k

-US$10m

Sep 30 2024n/an/a

-US$9m

Jun 30 2024n/an/a

-US$9m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$950kUS$338k

-US$9m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$11m

Dec 31 2022US$795kUS$231k

-US$13m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$14m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021US$82kn/a

-US$12m

Compensation vs Market: Miranda's total compensation ($USD1.48M) is above average for companies of similar size in the US market ($USD659.85K).

Compensation vs Earnings: Miranda's compensation has increased whilst the company is unprofitable.

CEO

Miranda Toledano (49 yo)

4yrs
Tenure
US$1,482,000
Compensation

Ms. Miranda J. Toledano, M.B.A. serves as Chief Executive Officer of Entera Bio Ltd. since July 15, 2022. She serves as an Independent Director of Journey Medical Corporation since June 2021.She served as...

Leadership Team

NamePositionTenureCompensationOwnership
Miranda Toledano
CEO & Director4yrsUS$1.48m0.87%
$ 708.1k
Hillel Galitzer
Chief Operating Officer12.4yrsUS$531.00k0.18%
$ 150.4k
Gregory Burshtein
Chief of Research & Development2.2yrsUS$504.00k0.21%
$ 168.4k
Dana Yaacov-Garbeli
Chief Financial Officer7.1yrsUS$438.00k0.23%
$ 187.7k
Rachel Wagman
Chief Clinical Advisor2.2yrsno datano data
Cherin Smith
Executive VP & Head of Clinical Operations1.5yrsno datano data
Constantin Itin
Head of Biopharmaceutics & Bioanalytics1.5yrsno datano data
2.2yrs
Average Tenure
48.5yo
Average Age

Experienced Management: ENTX's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Miranda Toledano
CEO & Director7.8yrsUS$1.48m0.87%
$ 708.1k
Steven Goldstein
Member of Clinical & Scientific Advisory Board3.3yrsno datano data
Steven Rubin
Independent Directorless than a yearno data0.030%
$ 24.9k
Geno Germano
Independent Chairmanless than a yearno data0.081%
$ 66.4k
Yonatan Malca
Independent Director15.5yrsUS$103.77k0.12%
$ 98.6k
Haya Taitel
Non-Employee Independent Director3.1yrsUS$98.66k0.20%
$ 163.5k
Sean Ellis
Independent Director7.1yrsUS$94.48k0.38%
$ 312.2k
John Bilezikian
Member of Scientific Advisory Boardno datano datano data
Maria Brandi
Member of Scientific Advisory Boardno datano datano data
Felicia Cosman
Chairman of Scientific Advisory Board3.7yrsno datano data
Serge Ferrari
Member of Scientific Advisory Board2.5yrsno datano data
Bente Langdahl
Member of Scientific Advisory Board2.5yrsno datano data
3.2yrs
Average Tenure
63yo
Average Age

Experienced Board: ENTX's board of directors are considered experienced (3.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 10:00
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Entera Bio Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
null nullCG Capital
Raghuram SelvarajuH.C. Wainwright & Co.